MAIA
MAIA Biotechnology, Inc.stockNYSEAMERICAN
maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia's business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia's business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.09 | 2026-11-09 | -10.74% | 0.180 |
| 1M | 1.10 | 2026-10-16 | -11.55% | 1.829 |
| 3M | 1.39 | 2026-08-17 | -30.00% | 1.628 |
| 6M | 1.26 | 2026-05-15 | -22.78% | 1.788 |
| 1Y | 1.00 | 2025-11-17 | -2.71% | 1.603 |
| 2Y | 2.26 | 2024-11-15 | -56.95% | — |
| 5Y | 4.46 | 2022-07-28 | -78.19% | 0.709 |
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) stock price today is $0.97, and today's volume is 293,400. MAIA is down 2.705% today. The 30 day average volume is 304,420. MAIA market cap is $60.08M with 61.75M shares outstanding.